Chinese Drug Maker Thousand Oaks Biopharmaceuticals Nets $44M In Series A Round

Login to View

Chinese therapeutics medicine developer Thousand Oaks Biopharmaceuticals Co. announced yesterday that they have completed a RMB300 million (US$43.61 million) series A round of financing, led by New Alliance Capital, according to a company statement.

Continue reading with a China Money Network subscription

Join Now

Already have an account or paid subscription? Log in